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Abstract
metabolic syndrome (ms) consists of multiple cardiometabolic risk factors that tend to aggregate in an individual more often 
than only by chance. It frequently coexists with type 2 diabetes mellitus (T2Dm). The aim of the present study is to characterize 
the prevalence of ms and its traits, as well as the modalities of clustering of the components, in 1111 (49.6% female, 50.4% male; 
mean age of 59 years) newly diagnosed T2Dm patients from an outpatient diabetes clinic. according to the International Dia-
betes Federation (IDF)’s definition, the abdominal obesity is one of “any three of five characteristics” in a person with ms. as all 
our patients were diabetics, in order to be defined as having ms they must have had a waist circumference ≥ 94 cm for men and 
≥80 cm for women and at least one of any of the following factors: elevated triglycerides: ≥150 mg/dl or specific treatment for 
this lipid abnormality; decreased hDl-cholesterol: <40 mg/dl in men; <50 mg/dl in women, or specific treatment for this lipid 
abnormality; high blood pressure: systolic blood pressure ≥130 and/or diastolic blood pressure ≥85 mm hg, or antihypertensive 
drug treatment. In the latest published consensus definition the visceral obesity is no longer an obligatory component for ms 
diagnosis, three or more of the following criteria must be met: (i) abdominal obesity: increased waist circumference, (ii) elevated 
triglycerides: ≥150 mg/dl, (iii) decreased hDl-cholesterol: <40 mg/dl in men, <50 mg/dl in women, (iv) increased blood pres-
sure systolic ≥130 and/or diastolic ≥85 mm hg, and (v) increased fasting glucose > 100 mg/dl. metabolic syndrome incidence 
was high, no matter what definition was used: 89.7% (IDF’s definition), 92.3% (the 2009 harmonized definition with a cut-off 
value for waist of 80 cm in women and 94 cm in men) and 88.6% (the 2009 harmonized definition with a cut-off value for waist 
of 88 cm in women and 102 cm in men). The concordance between the three definitions was 85.3% (higher in women). most 
of the patients with ms fulfilled four of the criteria. beside hyperglycemia, the decreasing frequency of ms traits was: increased 
waist circumference (96.4%), high blood pressure (84.8%), low hDl cholesterol (63.9%) and high triglycerides (57.9%). among 
patients with ms, the increased waist and low hDl cholesterol were more frequent findings in women than in men, while hip-
ertriglyceridemia was more frequent in men. mean value for both systolic and diastolic pressure were higher in women. In sum, 
the results underline the high prevalence of ms among subjects with newly diagnosed T2Dm and in majority of cases, four com-
ponents are clustering. The clustering appears to be dependent on excess of visceral adipose tissue and has a different pattern 
depending on gender.
Adipobiology 2012; 4: 91-96
Keywords: cardiometabolic risk, definition, prevalence
Adipobiology
ISSN 1313-3705
© Bul garian Society for Cell Biology
ASSESSmENt of mEtAboliC SyNDromE CompoNENtS  
iN NEWly DiAgNoSED typE 2 DiAbEtES
1,2Doina Andrada Mihai, 3Iuliana Filip, 2Elena Caceaune, 4Daniela Drăgoescu, and 2Constantin Ionescu-
Tirgoviste 
1university of medicine and pharmacy “carol Davila” bucharest, 2“n. paulescu” Institute of Diabetes, nutrition and 





Metabolic syndrome in diabetes92 ReseaRch aRticle
introduction 
Metabolic syndrome (MS) consists in multiple cardiometabol-
ic risk factors that tend to aggregate more often than only by 
chance. It frequently coexists with type 2 diabetes, and in this 
combination, the risk is increased even more (1). The MS com-
ponents include elevated glycemia (type 2 diabetes included), 
atherogenic dyslipidemia, elevated blood pressure, a prothrom-
botic and a proinflammatory state (2, 3). The MS is commonly 
affecting about 25-30% of the general population in Europe 
(4-9) and the prevalence is increasing. The prevalence is even 
higher in people with type 2 diabetes, varying between 70 and 
91.5% depending on witch definition was used or the type of 
population studied (10-14). 
The aim of the present study is to determine the prevalence 
of MS and to characterize its traits in an adult population of 
newly diagnosed type 2 diabetic patients. Another objective was 
to describe the modalities of clustering the components of the 
metabolic syndrome in this population and to examine if there 
are differences between genders. As the prevalence varies with 
different definitions, we used the 2005 International Diabetes 
Federation (IDF) criteria (3) and the consensus definition of the 
IDF and the American Heart Association, National Heart, Lung, 
and Blood Institute, World Heart Federation, International Ath-




We included in our study 1111 subjects with newly discovered 
type 2 diabetes from an outpatient diabetes clinic. The subjects, 
aged 30–89 years, with a similar gender distribution (551-49.6% 
female, 560-50.4% male) were entered into a descriptive, cross-
sectional analysis with the aim to characterize the prevalence of 
MS and its traits. The subjects were referred to the diabetes clinic 
by their general practitioners, by other specialists or by self re-
ferral. Initially we entered all consecutive patients that were reg-
istered at the clinic with newly diagnosed type 2 diabetes, during 
18 months, but we kept for the analysis only the subjects with 
complete clinical, anthropometric, and biochemical data. 
Methods
The subject’s data were recorded during the visit at the clinic. 
The data about lifestyle, family history, personal medical his-
tory, and concomitant medication were noted. The physical ex-
amination included weight (in light clothing), height (barefoot), 
waist circumference (measured with the subject standing, at mid 
distance between the lowest rib and the iliac crest, at the end 
of normal expiration), and blood pressure measurements. The 
body mass index (BMI) was calculated as weight (kg)/ height 
(m2). Fasting venous blood samples were taken to determine 
serum glucose, total cholesterol, triglycerides (TG), high den-
sity cholesterol (HDL-chol), creatinine, transaminases (AST, 
ALT), and glycated hemoglobin (HbA1c). Low density choles-
terol (LDL-chol) was calculated using Friedewald formula. The 
samples were analyzed at the center’s laboratory. The history of 
cerebrovascular disease was of particular interest (documented 
coronary heart disease, previous myocardial infarction, stroke, 
peripheral arterial disease).
According to the IDF definition (3), the central (abdominal) 
obesity is mandatory for diagnosis of the MS. As all our patients 
were diabetics, in order to be defined as having MS they must 
had have a waist circumference ≥ 94 cm for men and ≥80 cm for 
women and any at least one another factor of the following fac-
tors: elevated triglycerides: ≥150 mg/dL or specific treatment for 
this lipid abnormality; decreased HDL-cholesterol: <40 mg/dL 
in men; <50 mg/dL in women, or specific treatment for this lipid 
abnormality; high blood pressure: systolic blood pressure ≥130 
and/or diastolic blood pressure ≥85 mm Hg, or antihypertensive 
drug treatment.
In the latest published consensus definition (15) the central 
obesity is no longer an obligatory component. In order to estab-
lish MS diagnosis, three or more of the following criteria must 
be met: (i) abdominal obesity: increased waist circumference, 
(ii) elevated triglycerides: ≥150 mg/dL or specific treatment for 
this lipid abnormality, (iii) decreased HDL-cholesterol: <40 mg/
dL in men, <50 mg/dL in women, or specific treatment for this 
lipid abnormality, (iv) increased blood pressure systolic ≥130 
and/or diastolic ≥85 mm Hg, or antihypertensive drug treat-
ment in patient with history of hypertension, and (v) increased 
fasting glucose > 100 mg/dL, or drug treatment of increased glu-
cose. All of our patients had diabetes so they had one compo-
nent of the syndrome. For waist circumference in Europeans it 
is recommended that either the IDF or AHA/NHLBI cut points 
to be used. At waist circumference of ≥ 94 cm for men and ≥80 
cm for women (IDF cut points), the risk is increased (consen-
sus definition I); but the risk is substantially greater when the 
waist circumference is ≥102 cm for men and ≥88 cm for women 
(AHA/NHLBI cut points). We tested both sets of cut points in 
our study population. The drugs used for increased triglycerides 
and reduced HDL cholesterol were fibrates. We considered those 
using high-dose of ω-3 fatty acids as having high triglycerides.
Statistical analysis
The statistical analysis was performed with Epi Info 7.1.0.6 sta-
tistical software (Centre for Disease Control, Atlanta). First we 
realized a descriptive analysis of the variables. The population 
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clinical and biochemical characteristics were presented as mean 
± standard deviation. Variables values were compared between 
women and men, and between those with or without the meta-
bolic syndrome. A p value of <0.05 was considered to indicate a 
significant difference. We also identified a metabolic syndrome 
component association.
results
The clinical and metabolic characteristics of patients are pre-
sented in Table 1. The mean age was 59 years, women being 
slightly older (p<0.05) than men. Women had higher BMI and 
waist circumference than the women. For the metabolic charac-
teristics, men had significantly higher values for serum triglyc-
erides and transaminases (p<0.05).
Metabolic syndrome prevalence was high no matter what 
definition was used, but there were different prevalence rates ac-
cording to the different definitions. Respectively, the prevalence 
was: 89.7% (IDF definition), 92.3% (the harmonized definition 
with a cut off value for waist of 80 cm in women and 94 cm 
in men) and 88.6% (the harmonized definition with a cut off 
value for waist of 88 cm in women and 102 cm in men). The 
harmonized definition with a cut off value for waist of 80 cm 
in women and 94 cm in men indicates greater prevalence than 
other definitions. 
Taking into consideration the number of the criteria fulfilled 
for MS definition, it was noticed that no matter what definition 
was used most of the patients identified with metabolic syn-
drome have fulfilled four criteria. In the IDF’s definition, on the 
second position as frequency are placed the patients that ful-
filled five criteria. In the harmonized definition, on the second 
position as frequency are placed the patients that fulfilled three 
criteria. After diabetes, which was present in all patients, the 
next most frequent MS trait was increased waist circumference, 
being present in 94,2% of subjects if the IDF cut points were 
used, or in 80,9% of subjects if the AHA/NHLBI cut points were 
used. The highest proportion of subjects with waist trait present 
and identified as having metabolic syndrome was noticed for the 
harmonized definition with a cut off value for waist of 88 cm in 
women and 102 cm in men (96.4%).
The concordance between the three definitions was 85.3%. 
Agreement between different definitions was higher for women 
than for men, as described also in other diabetic populations 













BMI* (kg/m2) 32,711 6,1451 30,475 5,1898 0,000 31,584 5,7901
Waist* (cm) 105,17 12,998 107,94 12,124 0,000 106,57 12,635
Total cholest (mg/dL) 218,92 54,28 216,09 58,15 ns 217,49 56,259
HDL-chol*
(mg/dL)
46,14 13,08 40,72 11,24 0,000 43,41 12,488
LDL-chol
(mg/dL)
138,22 48,586 134,68 44,126 ns 136,49 46,468
Non HDL-chol
(mg/dL)
172,77 54,075 175,37 57,910 ns 174,09 56,031
TG* (mg/dL) 180,85 149,81 212,18 188,79 0,000 196,65 171,21
AST* (UI/L) 25,21 14,022 27,38 15,325 0,014 26,31 14,726
ALT* (UI/L) 29,60 17,97 34,18 19,69 0,000 31,91 18.99
AST/ALT* 0,938 0,349 0,893 0,407 0,049 0,916 0,379
SerumCreatinine*
(mg/dL)
0,74 0,200 0,92 0,201 0,000 0,83 0,218
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(14). The consensus (harmonized) definition with a cut-off val-
ue for waist of 88 cm in women and 102 cm in men tended to 
identify more associated metabolic disturbances, although not 
reaching statistical significance. For this reason and for the fact 
that all MS traits appeared with higher frequency than in the 
other two compared definitions (p<0.05) we further analyzed 
the data referring only to this definition. 
In our study population, women with MS were more numer-
ous than men (52.4% vs. 47.6%, p<0.05). Different published 
papers reported different gender distribution of the metabolic 
syndrome.
In literature, it was described an increasing prevalence of MS 
with increasing age (17, 18). The age distribution of patients 
with MS is presented in Figure 1. According to this distribution 
it can be concluded that 4 out of 10 patients with MS are placed 
in the group 50-59 years and 3 out of 10 patients in the group 
60-69 years. 
Most of the patients with MS fulfilled four of the criteria. 
Beside hyperglycemia, the decreasing frequency of metabolic 
syndrome traits was: increased waist circumference (96.4%), 
high blood pressure (84.8%), low HDL cholesterol (63.9%) and 
high triglycerides (57.9%). The frequency of the individual MS 
criteria fulfilled had significant difference between genders for: 
large waist circumference, low HDL cholesterol - more frequent 
in women, elevated triglycerides – more frequent in men. The 
frequencies of different MS traits are presented in table 2. Mean 
value for both systolic and diastolic pressure were higher in 
women (p<0.05).
The component association was different depending on 
gender. In women the following ranking of components asso-
ciations was observed: 34.1% associated increased waist, high 
blood pressure, increase triglycerides, low HDL cholesterol, 
23.1% associated increased waist, high blood pressure, low HDL 
cholesterol, and 19.6% associated only increased waist and high 
blood pressure. The profile is significantly different for men, 
where the ranking of components associations is: 27.1% asso-
ciated increased waist, high blood pressure, increase triglycer-
ides, low HDL cholesterol, 18.6% associated increased waist and 
high blood pressure, and 13.7% associated increased waist, high 
blood pressure, low HDL cholesterol.
Discussion
The concept of MS is nowadays identifying centrally obese peo-
ple with increased risk for cardiovascular disease and, if not 
already present, type 2 diabetes. Although there are different 
definitions in use, and the prevalence of the MS varies with the 
definition used, it is no doubt that its prevalence is high and in-
creasing all over the world. In special populations like patients 
with type 2 diabetes, the reported prevalence is even higher (10-
14), the syndrome being closely associated with type 2 diabetes. 
In our study, the prevalence was: 89.7% (IDF’s definition), 92.3% 
(the harmonized definition with a cut off value for waist of 80 
cm in women and 94 cm in men) and 88.6% (the harmonized 
definition with a cut off value for waist of 88 cm in women and 
102 cm in men). The prevalence was higher in women than in 
men (52.4% vs. 47.6%, p<0.05). Other published papers reported 
different gender distribution of MS. Some of the studies in Euro-
pean subjects reported higher prevalence in women, similar to 
our findings (14, 16), while others reported higher prevalence in 
men (11). The highest prevalence was noticed for subjects aged 
50-59 years, followed by subjects aged 60-69 years, and by the 
subjects older then 70 years.
The MS traits clustered in studied patients, most of them 
fulfilling four criteria. After diabetes, the most common MS 
trait was large waist circumference, underling the importance 
of central obesity in these patients. We further analyzed gen-
der differences in our patients. Among those with metabolic 
syndrome, the increased waist and low HDL cholesterol were 
more frequent findings in women than in men (p<0.05), while 
hipertriglyceridemia was more frequent in men (p<0.05). The 









Age group (years old)
Figure 1. age distribution of patients with metabolic 
syndrome.
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Women fulfilling the criteria
n (% of total subjects fulfilling the criteria) 492 (56.7%) 446 (53.4%) 357 (56.8%) 275 (48.2%)
% within all women 95.3% 86.4% 69.2% 53.3%
Men fulfilling the criteria
n (% of total subjects fulfilling the criteria) 375 (43.3%) 375 (43.3%) 272 (43.2%) 295 (51.8%)
% within all men 80.1% 83.1% 58.1% 63.0%
Total subjects fulfilling the criteria N 867 835 629 570
p=0.000; # p=0.001; § p=0.087, ns.
We identified a different pattern of the components clustering in 
females versus males.
Conclusion
The results underline the high prevalence of MS among subjects 
with newly diagnosed type 2 diabetes and the fact that in ma-
jority of cases, four components are clustering. The clustering 
appears to be dependent on visceral adiposity and has a differ-
ent pattern depending on gender. The identification of traits of 
MS at the time of diagnosis of type 2 diabetes might be a useful 
tool for identifying subjects having an increased (global) cardo-
metabolic risk. A high disease burden is increased taking into 
account that MS is often associated with other disorders such 
as advanced atherosclerosis, nonalcoholic fatty liver disease or 
polycystic ovary syndrome. The recognition of MS in patients 
with type 2 diabetes from the time of its diagnosis is an impor-
tant “preventive” measure in an integrated approach aimed at 
the reduction of associated comorbidities and disease costs.
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